XTL Biopharmaceuticals Ltd.

Healthcare · Biotechnology · Israel

Last price 1.61 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.90M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company’s lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies...